Anna Cereseto
University of Trento (Povo, Trento)
Anna Cereseto, PhD is the Principal Investigator of the Laboratory of Molecular Biology at the University of Trento and serves as the Vice Director of the Department CIBIO. She earned her degree in Biological Sciences from the University of Genoa in 1990, after which she moved to the National Institutes of Health (NIH) in Bethesda, MD, USA, to study the molecular biology of retroviruses. In 1998, Dr. Cereseto undertook a postdoctoral position at Cornell University and became an instructor at the Institute of Gene Therapy at Mount Sinai School of Medicine in New York. In 2000, she returned to Italy, working at the Istituto Superiore di Sanità (ISS) in Rome before joining the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste. In 2003, Dr. Cereseto moved to the Scuola Normale Superiore (SNS) in Pisa as an Assistant Professor, and in 2010, she became a Professor at the University of Trento. At Trento, she leads a biotechnology research group focused on genome editing for gene therapy, with a particular emphasis on cystic fibrosis.
In 2018, she founded Alia Therapeutics, a startup focused on developing genome editing-based treatments. Dr. Cereseto has published over 60 scientific papers, and her research is supported by the Italian Ministry of Research, the European Union, and the Cystic Fibrosis Foundations in both Italy and the US.